加减平胃四逆方联合恩替卡韦治疗乙型肝炎失代偿期肝硬化临床研究  

Clinical efficacy of modified prescription of pingweisini combined with entecavir on patients at decompensation stage of liver cirrhosis

作　　者：张燕霞 张晋波 

机构地区：[1]山西省晋城市第三人民医院肝病科,山西晋城048000 [2]山西省晋城市人民医院中医科,山西晋城048000

出　　处：《中国肝脏病杂志（电子版）》2014年第4期39-41,共3页Chinese Journal of Liver Diseases：Electronic Version

摘　　要：目的观察加减平胃四逆方联合ETV治疗乙型肝炎失代偿期肝硬化的临床疗效。方法将50例乙型肝炎失代偿期肝硬化患者分为治疗组和对照组各25例,对照组给予综合治疗并口服ETV分散片0.5 mg/次,每日1次;治疗组在此基础上加服加减平胃四逆方,每日1剂,分两次服用。两组患者疗程均为24周。观察患者治疗前后肝功能、PTA、HBV DNA定量、Child-Pugh评分变化情况。结果治疗组在改善肝功能、PTA、降低Child-Pugh评分方面疗效显著优于对照组;在HBV DNA低于检测下限的比率方面,两组差异无统计学意义。结论加减平胃四逆方联合ETV治疗乙型肝炎失代偿期肝硬化在改善肝功能、PTA、降低Child-Pugh评分方面疗效确切。Objective To investigate the effect of modified prescription of pingweisini combined with entecavir（ETV） on patients at decompensation stage of liver cirrhosis. Methods Total of 50 cases were randomly divided into control group and treatment group with 25 cases per group. The control group received comprehensive therapy and ETV 0.5 mg/d, once a day, while the treatment group was treated with ETV 0.5 mg/d, once a day and modifi ed prescription of pingweisini twice a day for 24 weeks besides the comprehensive therapy. Liver function, prothrombin time activity（PTA）, quantitative level of HBV DNA and Child-Pugh scale was were assessed before and after treatment. Results Compared with control group, the liver function, PTA was improved, score of Child-Pugh scale was decreased in treatment group; there is no signigicant difference in inhibiting HBV of both groups. Conclusions Combined therapy of modifi ed prescription of pingweisini and ETV on treatment of decompensation stage of hepatic cirrhosis, especially in improving liver function, prothrombin time activity（PTA） and inhibiting HBV, had curative effect.

关 键 词：恩替卡韦 肝炎 乙型 肝硬化 

分 类 号：R512.62[医药卫生—内科学] R575.2[医药卫生—临床医学]